Tango Therapeutics
TNGX
72 hedge funds and large institutions have $528M invested in Tango Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
24% more funds holding
Funds holding: 58 → 72 (+14)
2.18% more ownership
Funds ownership: 77.41% → 79.59% (+2.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $741M → $528M (-$213M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$10.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.67M |
| 4 |
SCA
Southpoint Capital Advisors
New York
|
+$6.98M |
| 5 |
Millennium Management
New York
|
+$4.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$25.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.66M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.65M |
| 4 |
RI
RTW Investments
New York
|
-$1.98M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$546K |
TNGX Hedge Fund Activity: Q1 2022 in Review
72 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2022, worth a combined $528M — down 29% from $741M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TNGX positions and 6 closed out — a net gain of 14 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11M. The largest seller was HHLR Advisors, cutting an estimated $25.9M.
- 72 institutional investors held Tango Therapeutics (TNGX) as of Q1 2022, up from 58 in Q4 2021.
- Funds reported $528M of Tango Therapeutics stock for Q1 2022, down 29% quarter-over-quarter.
- 20 funds opened new Tango Therapeutics positions in Q1 2022 and 6 closed out, a net change of +14 holders.
- The largest Tango Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $11M added.
- The largest Tango Therapeutics seller in Q1 2022 was HHLR Advisors, an estimated $25.9M sold.
Based on aggregated 13F filings for Q1 2022.